Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules

2026-04-17 · Source: The AI Journal · Field: Finance & Economics — Capital Markets & Investment Management, Corporate Finance & Treasury · Depth: Advanced, medium

Summary

Enveric Biosciences, Inc. (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small-molecule therapeutics, has closed a private placement offering. The offering involved the sale of 2,222,223 shares of common stock (or pre-funded warrants) and accompanying Series I and Series J warrants, all priced at $2.25 per share (or pre-funded warrant) and accompanying warrants. The warrants have an exercise price of $2.00 per share and are immediately exercisable. The Series I warrants expire five years after the Resale Registration Statement's effective date, while the short-term Series J warrants expire eighteen months after. The offering generated approximately $5 million in gross proceeds, with a potential for an additional $8.9 million if all warrants are fully exercised. H.C. Wainwright & Co. served as the exclusive placement agent, and Enveric intends to use the net proceeds for product development, working capital, and general corporate purposes.

Key takeaway

For investors evaluating biotechnology companies, Enveric's recent private placement provides an immediate $5 million capital injection, with a clear path to an additional $8.9 million if warrants are exercised. You should monitor the company's progress in product development and its use of these funds, as the exercise of warrants is not guaranteed and depends on future performance and market conditions.

Key insights

Enveric Biosciences secured $5 million upfront with potential for $8.9 million more via a private placement of stock and warrants.

Principles

• Private placements offer capital via unregistered securities.
• Warrants provide future capital potential at a set price.

Method

Enveric issued common stock/pre-funded warrants alongside Series I and Series J warrants in a private placement under Section 4(a)(2) and Regulation D.

In practice

• Consider private placements for capital generation.
• Utilize warrants to attract investors with future upside.

Topics

• Enveric Biosciences
• Private Placement
• Common Stock
• Warrants
• Neuroplastogenic Therapeutics

Best for: Investor, Executive, Legal Professional

Related on AIssential

• WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering — bioAffinity Technologies secured \$3.2 million through a public offering, facilitated by WallachBeth Capital, to advance its biotechnology initiatives.
• What happened to Anthropic? — Unauthorized secondary sales of private company stock are void without explicit board approval, posing significant fraud risks.
• Missile Startup Founded by SpaceX Alumni Targets $12 Billion Valuation — Defense tech startups, particularly those with SpaceX lineage, are attracting multi-billion dollar valuations.
• Euan Blair’s Multiverse boosts valuation with $70m fundraise — Multiverse secured $70M in funding, boosting its valuation to $2.1B despite prior layoffs and a business model pivot.
• OpenAI makes move to go public one week after rival Anthropic — Leading AI developers are pursuing IPOs to secure the vast capital needed for advanced model development and infrastructure.
• Spacetech EnduroSat eyes $200m Series C months after last round, sources say — EnduroSat's swift $200M Series C pursuit underscores intense competition and rapid capital demands in the satellite data and infrastructure market.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.